David N. Gill - Oct 5, 2021 Form 4 Insider Report for Strongbridge Biopharma plc (SBBP)

Role
Director
Signature
/s/ Judith Goldberg, as attorney-in-fact
Stock symbol
SBBP
Transactions as of
Oct 5, 2021
Transactions value $
$0
Form type
4
Date filed
10/6/2021, 07:41 PM
Previous filing
Oct 5, 2021
Next filing
Jan 26, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction SBBP Ordinary Shares Disposed to Issuer -78.1K -100% 0 Oct 5, 2021 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Ordinary shares of Issuer were converted into shares of common stock of Xeris Biopharma Holdings, Inc. ("HoldCo") pursuant to the Transaction Agreement (the "Agreement"), dated May 24, 2021, among the Issuer, Xeris Pharmaceuticals, Inc., HoldCo and Wells MergerSub, Inc. Under the Agreement, each ordinary share of Issuer was exchanged for 0.784 of a share of HoldCo common stock, and cash in lieu of fractional shares, plus one contingent value right (a "CVR") worth up to an additional $1.00, payable in cash, HoldCo common stock or a combination thereof at HoldCo's sole election.